OnQ Prostate -Breakthrough Software Supporting Improved Prostate Cancer Detection
OnQ Prostate is FDA-cleared post-processing software that supports improved detection of clinically significant prostate cancer. Leveraging an advanced diffusion MRI technique called Restriction Spectrum Imaging, powered by AI, the software enables faster, more accurate PI-RADS scoring.
Early detection of cancer improves survival by enabling treatment at the earliest possible stage.
Unfortunately, most cancers are still detected at later stages when chances of survival are diminished. This year alone, more than 1.7 million people are expected to be diagnosed with cancer in the United States.
See what could have been missed.
Color Fusion Map
Automatically fuses the Restricted Signal Map with the anatomical image series to support anatomical localization.
Restricted Signal Map
Shows areas of restricted diffusion with increased conspicuity compared to high b-value DWI.
How can OnQ Prostate improve your diagnosis?
- McCammack KC, Kane CJ, Parsons JK, et al. In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI. Prostate Cancer Prostatic Dis. 2016;19(2):168-173. doi:10.1038/pcan.2015.61
- McCammack KC, Schenker-Ahmed NM, White NS, et al. Restriction spectrum imaging improves MRI-based prostate cancer detection. Abdom Radiol (NY). 2016;41(5):946-953. doi:10.1007/s00261-016-0659-1
Diagnose & Plan Earlier
Easily discriminate prostate cancer from normal prostate tissue
Accurate Detection
Improves correlation with Gleason Score
Improve PI-RADS Performance
Has been shown to improve detection compared to mpMRI alone and improve inter-reader agreement.
